Sandbox:Mitra3
Therapuetic Considerations in RVMI | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reperfusion | Maintenance of RV preload | Decreased RV afterload | Restoring Rate/Rhythm and AV synchrony | Inotropic support | Mechanical Circulatory Support | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
•Thrmobolytics •Percutaneous coronary intervention (PCI) | • Avoidance of preload reducing agents, such as:
• In patients with hypotension (without pulmonary congestion):
| • Systemic or pulmonary vasodilators: | • In patients with bradyarrhthmias: • In patients with atrioventricular block:
| • In patients with refractory hypotension:
| May be needed in patients with cardiogenic shock secondary to RVMI:
| {{{ }}} | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||